HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    

Profit from the Pros – Zacks Free Email Newsletter
Our free email newsletter is filled with timely stock picks and market commentary. Sign up for free. Already on board? Check out the archive.
Quote:
Login Free Membership
Search:

 
Analyst Blog  

AGN's Wrinkles Need Smoothing

September 23, 2008 | Comments: 0
Recommended this article (1)
AGN
Print    Share

Allergan, Inc. (AGN - Analyst Report) recently announced that it has completed a top-line analysis of its two phase III clinical trials exploring the use of Botox for the prophylactic treatment of headache in adults suffering from chronic migraine.

From a fundamental standpoint, we are enthusiastic about the future of Allergan. The company possesses a strong blockbuster product in Botox and a slew of innovative new products in the eye and skin care markets. Both Botox and Juvederm should help the company strengthen its position in the dermatology and plastic surgery market. We were also pleased to hear about the U.S. approval of silicone breast implants.

We believe its recent acquisitions will provide Allergan with the opportunity to drive growth in its existing business and to expand into new areas of business. Even in the face of slowing consumer spending in the U.S., the company's presence across different segments and geographies should help maintain decent growth going forward.

Although the shares reacted positively to the recently released top-line results on Botox for the treatment of migraine, we believe that several issues are likely to keep a lid on the share price in the near-term. These issues include safety concerns surrounding the use of Botox and a subpoena from the Department of Justice, U.S. Attorney's Office for the Northern District of Georgia, related to promotional, educational and other activities for Botox. We maintain a Hold rating on the stock with a price target of $62.

Arpita Dutt, CA, contributed to the report.

Read the full analyst report on AGN


Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!

More Zacks Resources

Market Summary Nov 08, 2009 14:15 pm ET
DJIA 10023.42  17.46 0.17%
NASD 2112.44  7.12 0.34%
S&P 500 1069.3  2.67 0.25%
Sponsored Links